Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Swissmedic Grants Debiopharm Marketing Authorisation For Moapar(R), A New Therapeutic Avenue For The Treatment Of Sexual Deviations
Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, announced that the Swiss agency for therapeutic products, Swissmedic, has issued a marketing authorisation for Moapar(R) 11.25mg, the first 3-month injectable formulation, prescribed for a reversible reduction of serum testosterone to the level of castration in adult men suffering from sexual deviations. Developed by Debiopharm, Moapar(R) contains a gonadotropin-releasing hormone (GnRH) agonist analogue.

Social Security Administration Considers Adding Alzheimer's To Its Compassionate Allowances List
Today there are an estimated 5.3 million Americans with Alzheimer"s disease. Although the majority of Alzheimer cases are individuals age 65 and older, there is still a significant number of individuals under age 65 impacted by this fatal disease that today has no cure. For people under age 65 with Alzheimer"s disease or a related dementia, their cognitive impairment can quickly reach a point where they can no longer maintain gainful employment. The Alzheimer"s Association applauds the Social Security Administration (SSA) for holding a hearing today to examine whether these individuals with younger-onset Alzheimer"s disease or related dementias should be included in its Compassionate Allowances Initiative.
News of the day
Food Additive May One Day Help Control Blood Lipids And Reduce Disease Risk
Scientists at Washington University School of Medicine in St. Louis have identified a substance in the liver that helps process fat and glucose. That substance is a component of the common food additive lecithin, and researchers speculate it may one day be possible to use lecithin products to control blood lipids and reduce risk for diabetes, hypertension or cardiovascular disease using treatments delivered in food rather than medication.
Mental Health

Rotherham Nurse Raises Alarm Over Infant Medicine Feeder

A concerned Rotherham nurse has forced manufacturers of an infant medicine feeder to withdraw its product following a safety scare. Nurse Karen Ray, a clinical procurement specialist at Rotherham Hospital, took her concerns to the Medicines and Healthcare products Regulatory Agency (MHRA) after a six-month-old baby was admitted to Rotherham Hospital following a liquid paracetamol overdose. Karen Ray told the MHRA how she feared the First Steps feeder, manufactured by RSW International Ltd, was being distributed nationwide and sold for ÷£1 in discount retail outlets, and on eBay. RSW International have now recalled all remaining stock. Karen explained: "I was worried when I saw the medicine feeder about how confusing the measurements were. The measurements were in mls and teaspoons and it was really unclear which was which. "I immediately took my concerns to the MHRA and they contacted the manufacturers. Thankfully it has now been removed from sale." MHRA Director of Device Technology and Safety, Clive Bray, said he "strongly advised" people to stop using these medicine feeders which are marketed for the administration of liquid medicines to babies and young children. "There is no evidence that the safety, quality or performance of this product has been assessed to the current standard," he said. "The product could pose a potential risk to babies or young children as the measuring scale is confusing and could be inaccurate. "This may have caused the reported overdose and we are strongly advising parents to stop using, and dispose of this product." The Rotherham NHS Foundation Trust


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009